



Cancer and host immunity (microbiome)

Ivana Haluskova Balter

French society of immunology, France

Abstract

Gastrointestinal tract is crucial for many physiological processes it plays an important role in inflammatory and immune reactions. Several internal and external factors can influence this population, and shifts in their composition, have been demonstrated to contribute and affect different diseases. During dysbiosis several bacteria related to inflammation, one of the most necessary factors in carcinogenesis; it has been shown that some bacterial strains through deregulation of different signals/pathways may affect tumor development through the production of many factors. Gut microbiota might be considered as a holistic hub point for cancer development: direct and indirect involvements have been studying in several neoplasms such as colon rectal cancer, hepatocellular carcinoma and breast cancer. Immune host response and resistance microbiome is composed from 100.000 milliards of bacteria. It forms protective barrier against pathogens (permeability) and interactive layer with inner host immune system and neuroendocrine System. It does play important role in development (training of host immune response), human health prevention. There is an increasing scientific evidence of crosstalk between gut microbiota and cancer, its ability to modulate chemotherapy, radiotherapy and immunotherapy, and the possibility that the intestinal microbial is a new target for therapeutic approaches to improve the prognosis and quality of life of cancer patients and even prevent with accurate diagnostic escape from host immune surveillance. Many alternatives are ongoing including combination with immunotherapy, but personalised approach given genetic and immune specificities and biology of cancer are important. We try to modify the patient's microbiota in order to promote Notes: the immune response to reduce gastrointestinal toxicity, i.e. diarrhoea in patients who are candidates for chemo and radiotherapy, but without some studies they have linked the use of accurate intervention at host microbiome in particularly immunosuppressed patients and some important side effects. Treatments to improve the possibility of tolerance, on the one hand, and response on the other but we must consider all alternative and complexity of individual approach (genetic, medical background, resistance to treatment, French medical professional, and speaking French, English, Russian, Czech / Slovak and Italian. The use of diet and microbiota can be really interesting during cancer.

Biography

Ivana Haluskova Balter is specialized in infectious diseases, internal medicine, certified in Immunology and Pediatric, MBA vaccinology and years of clinical practice. She is certified in Health and Diplomacy with Lived multi-country medical "field" experience in Southeast Asia (India in particular), West/Central/East Europe. She has over 17 years of experience in senior medical lead positions in pharmaceutical research and development for European and USA companies for various therapeutic areas for adults and children. She is a member of the World alliance against antibiotic resistance and French immunology society (SFI) administrative board and several international academic societies with focus at innovation of R&D. reflecting immunology and genetic variability, role of immunologic approach for treatment and diagnostic to tackle problem of resistance and role of microbiota to empower host immune response with extensive clinical application and member of international advisory group (CHD India) in order to attract attention to crucial importance of health issues for sustainable economic development and security. She has years of expertise to work on project related to global health more focused at Eurasia and Asia (India in particular)

Publications

1. Ivana Haluskova Balter (2020) : Medicine, Prevention, treatment of chronic conditions and source of new entities in era of raising resistance- Ivana Haluskova Balter, Medical and science advisor for partnership, France. Medical Safety and Global Health
2. Ivana Haluskova Balter (2018) Microbial Pathogenesis 2018: Gut microbiota and Antibiotic resistance, Global Journal of Digestive Diseases
3. Ivana Haluskova Balter (2018) Tackling neglected diseases in current context, J Infect Dis Ther
4. Ivana Haluskova Balter (2018), Vaccines and infectious diseases, J Clin Exp Oncol
5. Ivana Haluskova Balter (2018) Vaccines To Tackle Antimicrobial Resistance, Asian J Biomed Pharmaceut Sci

17th International Conference on Oncology Nursing and Cancer Care
Edinburgh, Scotland | March 04-5, 2020

Citation: Ivana Haluskova Balter, *Cancer and host immunity (microbiome)*, Cancer Nursing 2020, 17th International Conference on Oncology Nursing and Cancer Care, Edinburgh, Scotland | March 04-05, 2020, 2471-2671-6:3-09